Drug class
Integrase Inhibitors clinical trials
A class of medicines: the studies that test any of its 11 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the integrase inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Bictegravir, emtricitabine, tenofovir alafenamide, drug combination
- 23
- Cabotegravir, rilpivirine drug combination
- 8
- Abacavir, dolutegravir, and lamivudine drug combination
- 6
- Dolutegravir, rilpivirine drug combination
- 2
Studies by the year they started
515 studies that test it; most in 2008 (43)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 16 |
| 2008 | 43 |
| 2009 | 34 |
| 2010 | 38 |
| 2011 | 29 |
| 2012 | 20 |
| 2013 | 22 |
| 2014 | 33 |
| 2015 | 43 |
| 2016 | 25 |
| 2017 | 23 |
| 2018 | 19 |
| 2019 | 29 |
| 2020 | 24 |
| 2021 | 29 |
| 2022 | 22 |
| 2023 | 17 |
| 2024 | 22 |
| 2025 | 8 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 189 · Other 326
ViiV Healthcare (98) · Gilead Sciences (44) · National Institute of Allergy and Infectious Diseases (NIAID) (22) · Merck Sharp & Dohme LLC (15) · ANRS, Emerging Infectious Diseases (11) · GlaxoSmithKline (10) · Radboud University Medical Center (9) · St Stephens Aids Trust (9)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 515
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as E/C/F/TAF
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05652478Written as Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)
- Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenRecruitingPhase 4Fundación HuéspedNCT07616739Written as Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
- Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentRecruitingPhase 3Johns Hopkins UniversityNCT06497465Written as Dolutegravir 50mg Tab
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as Raltegravir (RAL)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Dolutegravir (DTG)
- NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral SettingsNot yet recruitingPhase 4Duke UniversityNCT06854029Written as Cabotegravir Injection
- Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsRecruitingPhase 2Federal University of São PauloNCT06805656Written as Dolutegravir
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingPhase 3ViiV HealthcareNCT07393659Written as Dolutegravir (DTG)/ Lamivudine (3TC)
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionRecruitingPhase 1Brigham and Women's HospitalNCT06281834Written as Dolutegravir
- Optimization of Antiretroviral Therapy in Patients With AIDS-Related LymphomaRecruitingNot applicableShanghai Public Health Clinical CenterNCT07727642Written as Cabotegravir/Rilpivirine
- Cabotegravir-Hormone PK/PD Interactions for HIV PreventionRecruitingPhase 1Johns Hopkins UniversityNCT07672717Written as Cabotegravir Injectable Suspension (CAB LA)
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingPhase 3Africa Health Research InstituteNCT06250504Written as APRETUDE (cabotegravir) 600 mg\3 mL
- A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingPhase 1/2ViiV HealthcareNCT07275606Written as Oral CAB
- Kuwa Free! - Live Free!RecruitingNot applicableUniversity of Alabama at BirminghamNCT05044962Written as Cabotegravir/ Rilpivirine
- Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsRecruitingPhase 4Massachusetts General HospitalNCT07199335Written as APRETUDE (cabotegravir)
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingPhase 1ViiV HealthcareNCT05418868Written as Cabotegravir 200 mg/mL
See all 515 studies that test one of the integrase inhibitors →
Codes
What other systems call Integrase Inhibitors · ClinicalTrials.gg INT008703
- MeSH (NLM) D019429Integrase InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019429 | Integrase Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.